Kruger, Dinja T.
Beelen, Karin J.
Opdam, Mark
Sanders, Joyce
van der Noort, Vincent
Boven, Epie
Linn, Sabine C.
Funding for this research was provided by:
This work was supported by grants from TI Pharma (project number T3-502) and from A Sister’s Hope.
Article History
Received: 13 February 2018
Revised: 13 July 2018
Accepted: 17 July 2018
First Online: 5 October 2018
<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate
: The IKA trial was approved by the central ethics committee of the Netherlands Cancer Institute. Informed consent was obtained from all participating patients. The trial was performed in accordance with the Declaration of Helsinki. For this retrospective translational study, no additional consent was required according to Dutch legislation, since the use of anonymised archival pathology left-over material does not interfere with patient care. Tumour tissue was handled according to the Dutch code of conduct for responsible use of human tissue in the context of health research.
: This work was supported by grants from TI Pharma (Project number T3-502) and from A Sister’s Hope.
: S.C.L. is an advisory board member for AstraZeneca, Cergentis, Novartis, Roche and Sanofi. S.C.L. received institutional research support funding from Adienne, Amgen, AstraZeneca, Genentech, Roche, Tesaro and Sanofi. All other authors declare no competing interests.
: The data that support the findings of this study are available from the corresponding author upon reasonable request.